Biotech Screener: Finding FDA Catalyst Plays Before the Market Moves
A biotech screener is a tool for filtering the biotech universe to find companies with a specific combination of catalysts, signals, and risk profiles. Unlike a general stock screener that uses P/E ratios and revenue growth, an effective biotech screener uses FDA calendar data, regulatory pathway signals, and institutional activity patterns.
Why Biotech Screening Is Different
Standard stock screeners filter by financial metrics: earnings, growth, valuation. Biotech screening is fundamentally different. Most biotech companies have no earnings and minimal revenue. The variables that predict price movement are event-driven: upcoming PDUFA date, adcom history, Phase 3 probability, orphan drug status, and institutional accumulation patterns. A biotech screener must be built around these event-driven variables, not traditional financial ratios.
Key Biotech Screener Filters
The most powerful biotech screener filters are: (1) PDUFA date within 90 days — near-term catalyst with defined timing; (2) Orphan Drug Designation — smaller patient populations, higher pricing power, faster FDA review; (3) Breakthrough Therapy Designation — signals strong Phase 2 evidence and expedited FDA review; (4) Insider cluster buying — multiple executives buying within the same 30-day window; (5) Phase 3 completion date within the year — trial readout catalyst; (6) Market cap under $2B — larger potential price moves relative to size.
The Source-Backed Signal Approach
The most effective biotech screening methodology filters for source-backed signal overlap: multiple independent signals pointing in the same direction around the same catalyst date. A PDUFA date alone is an event. A PDUFA date plus recent insider buying plus orphan drug designation plus unusual current short-interest activity is a high-conviction setup. BiotechSign's screener is designed to surface this source-backed signal overlap across its signal library, not just show individual data points in isolation.
Filtering by Therapeutic Area
Biotech screening by therapeutic area helps manage sector-specific risk. Oncology has the highest PDUFA density but also the highest Phase 3 failure rate (~60%). Rare disease has smaller trials, faster FDA review, and higher pricing power. Neurology catalysts (Alzheimer's, ALS) carry high uncertainty but massive market size. Metabolic/obesity is currently the hottest area with strong commercial validation. BiotechSign's screener allows filtering by indication and disease area to match your risk profile.
Using BiotechSign's Biotech Screener
BiotechSign's screener lets you filter by upcoming catalyst timing, therapeutic area, regulatory designation, and signal type. You can screen for 'PDUFA within 60 days AND orphan drug AND insider buying in last 30 days' — a compound filter that identifies high-probability event setups. Screener results link directly to company pages showing the full signal picture: adcom history, filing timeline, and short-interest activity.
Screening for Risk Management
A biotech screener is also a risk management tool. Before entering any biotech position, screen for: total outstanding shares (dilution risk), cash runway relative to catalyst timing (fundraising risk), short interest as a percentage of float (squeeze potential), and historical volatility around prior catalysts. BiotechSign's company pages combine these risk factors with the signal data to give a complete pre-catalyst picture.
BiotechSign tracks FDA catalysts, PDUFA dates, adcom meetings, and biotech signals for 8,000+ companies in real time.
Open BiotechSign →